Journal of diabetes and its complications最新文献

SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-27 DOI: 10.1016/j.jdiacomp.2025.109021

Hasan Fehmi Özel , Şüheda Alpay , Emre Asker , Elif Sıdal Gültekin , Hasan Kazdağlı

{"title":"SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus","authors":"Hasan Fehmi Özel , Şüheda Alpay , Emre Asker , Elif Sıdal Gültekin , Hasan Kazdağlı","doi":"10.1016/j.jdiacomp.2025.109021","DOIUrl":"10.1016/j.jdiacomp.2025.109021","url":null,"abstract":"<div><div>Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have emerged as key therapeutic agents in managing type 2 diabetes mellitus (T2DM) and obesity, offering benefits that extend beyond glycemic control. This review examines the role of SGLT-2 inhibitors in modulating cardiac autonomic function, with a particular focus on heart rate variability (HRV) as a biomarker of autonomic balance. These agents improve metabolic profiles through enhanced glucosuria, natriuresis, and weight loss, while concurrently reducing blood pressure. Importantly, they also attenuate sympathetic nervous system overactivity and promote parasympathetic modulation, which may lower the risk of adverse cardiovascular events.</div><div>The underlying mechanisms include not only the metabolic effects but also anti-inflammatory and antioxidative actions, which together contribute to improved endothelial function and vascular health. Advanced HRV analyses, encompassing traditional time and frequency domain methods as well as nonlinear approaches, have proven valuable in detecting early autonomic dysfunction in high-risk populations. Some studies suggest that SGLT-2 inhibitors may be associated with improvements in HRV parameters, such as increased SDNN and RMSSD and a reduced LF/HF ratio. However, findings are inconsistent across studies, and further research is needed to determine the extent and mechanisms of these potential effects.</div><div>Although these findings are promising, further standardized, long-term studies are essential to clarify the mechanisms and optimal therapeutic strategies involving SGLT-2 inhibitors in the management of autonomic dysfunction. Future research should also explore the synergistic potential of combining SGLT-2 inhibitors with other cardiometabolic therapies to enhance cardiovascular outcomes in individuals with and without T2DM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109021"},"PeriodicalIF":2.9,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost effectiveness of topical wound oxygen therapy for chronic diabetic foot ulcers

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-24 DOI: 10.1016/j.jdiacomp.2025.109016

Marion Kerr , Daisy Wild , Michael Edmonds , Andrew J.M. Boulton

{"title":"Cost effectiveness of topical wound oxygen therapy for chronic diabetic foot ulcers","authors":"Marion Kerr , Daisy Wild , Michael Edmonds , Andrew J.M. Boulton","doi":"10.1016/j.jdiacomp.2025.109016","DOIUrl":"10.1016/j.jdiacomp.2025.109016","url":null,"abstract":"<div><h3>Aims</h3><div>To estimate the cost effectiveness of Topical Wound Oxygen therapy (TWO2) for chronic diabetic foot ulcers.</div></div><div><h3>Methods</h3><div>A Markov model was created to estimate the cost effectiveness of TWO2 over 2 years. Clinical outcome probabilities were estimated from a recent multi-national randomised controlled trial. Diabetic footcare costs were estimated for the National Health Service in England, based on national cost collections, published literature and expert opinion. Model inputs were varied in sensitivity analyses.</div></div><div><h3>Results</h3><div>Base case results indicate that at a weekly TWO2 price of £650 for up to 12 weeks, total diabetic footcare costs over 2 years are £5038 lower for a patient treated with TWO2 than for standard care, and QALYs are 0.07 higher. Probabilistic sensitivity analysis estimates an 81 % likelihood that the treatment is cost effective at a willingness to pay threshold of £25,000 per QALY.</div></div><div><h3>Conclusions</h3><div>Base case results indicate that if the clinical outcomes in the RCT are replicated in routine care, TWO2 is a dominant treatment, with lower cost and improved outcomes relative to standard care. Sensitivity analysis shows a high probability that the treatment is cost effective at a willingness to pay threshold of £25,000 per QALY.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109016"},"PeriodicalIF":2.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diabetic neuropathy in adolescents and young adults: The need for early detection and improved understanding.

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-24 DOI: 10.1016/j.jdiacomp.2025.109018

Prashanth R J Vas, Viviana Maggio, Manfredi Rizzo, Nikolaos Papanas

引用次数: 0

Contents/Barcode

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-22 DOI: 10.1016/S1056-8727(25)00062-5

引用次数: 0

The NGAL as a prognostic biomarker of kidney injury in children and adolescents with type 1 diabetes mellitus: A systematic review and meta-analysis

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-22 DOI: 10.1016/j.jdiacomp.2025.109002

Nikolaos Gkiourtzis , Anastasia Stoimeni , Panagiota Michou , Konstantinos Cheirakis , Maria Moutafi , Aristeidis Christakopoulos , Agni Glava , Paraskevi Panagopoulou , Georgios Tsigaras , Assimina Galli-Tsinopoulou , Athanasios Christoforidis , Despoina Tramma

{"title":"The NGAL as a prognostic biomarker of kidney injury in children and adolescents with type 1 diabetes mellitus: A systematic review and meta-analysis","authors":"Nikolaos Gkiourtzis , Anastasia Stoimeni , Panagiota Michou , Konstantinos Cheirakis , Maria Moutafi , Aristeidis Christakopoulos , Agni Glava , Paraskevi Panagopoulou , Georgios Tsigaras , Assimina Galli-Tsinopoulou , Athanasios Christoforidis , Despoina Tramma","doi":"10.1016/j.jdiacomp.2025.109002","DOIUrl":"10.1016/j.jdiacomp.2025.109002","url":null,"abstract":"<div><h3>Aims</h3><div>A major complication of type 1 diabetes is diabetic kidney disease (DKD). Albuminuria and impaired glomerular filtration rate are the main characteristics of DKD. Neutrophil gelatinase-associated lipocalin (NGAL) levels may rise even in the early stages of DKD, even in patients with normoalbuminuria. We present the first systematic review and meta-analysis examining the prognostic role of NGAL exclusively in pediatric patients with type 1 diabetes.</div></div><div><h3>Methods</h3><div>A search through major databases was carried out until September 24, 2024, investigating the prognostic role of NGAL in kidney injury in pediatric patients with type 1 diabetes. A <em>p</em> < 0.05 was considered statistically significant. A study quality assessment was conducted using the Newcastle-Ottawa Scale.</div></div><div><h3>Results</h3><div>The standardized mean difference in urinary NGAL (uNGAL) levels between the type 1 diabetes group and healthy controls was statistically significant (SMD = 0.63, 95%CI [0.36,0.90]). A moderate positive relationship between uNGAL and ACR was identified (<em>r</em> = 0.53, 95 % CI [0.31–0.70]). The uNGAL revealed a high overall diagnostic accuracy (AUC = 0.881).</div></div><div><h3>Conclusions</h3><div>Urinary NGAL appears to be a valuable biomarker for early detection and understanding of DKD in individuals with type 1 diabetes. Future clinical studies should prioritize assessing the accuracy of NGAL in identifying kidney injury in pediatric patients with type 1 diabetes and the association of NGAL with traditional biomarkers in groups with similar characteristics.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109002"},"PeriodicalIF":2.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143714987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Urogenital side effects in male subjects with type 2 diabetes treated with SGLT-2 inhibitors: A single centre, longitudinal observation 接受 SGLT-2 抑制剂治疗的男性 2 型糖尿病患者的泌尿生殖系统副作用：单中心纵向观察

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-22 DOI: 10.1016/j.jdiacomp.2025.109015

Alice Del Zoppo , Chiara Rovera , Giovanni Petralli , Diego Moriconi , Anna Solini

{"title":"Urogenital side effects in male subjects with type 2 diabetes treated with SGLT-2 inhibitors: A single centre, longitudinal observation","authors":"Alice Del Zoppo , Chiara Rovera , Giovanni Petralli , Diego Moriconi , Anna Solini","doi":"10.1016/j.jdiacomp.2025.109015","DOIUrl":"10.1016/j.jdiacomp.2025.109015","url":null,"abstract":"<div><h3>Objective</h3><div>SGLT-2 inhibitors (SGLT-2i) provide good glycaemic control and weight loss, ensuring clinically relevant cardiorenal benefits in subjects with and without type 2 diabetes (T2D); however, their use is related to an enhanced risk of urogenital infections, mainly in female subjects. We performed a prospective observation to assess incidence of urogenital complications in male sex new users of gliflozins.</div></div><div><h3>Subjects and methods</h3><div>In the 2021–2023 years, solely based on clinical indication, we started such therapy in 272 male T2D subjects; follow up visits were performed after about 1 year.</div></div><div><h3>Results</h3><div>At follow up, 90 subjects had discontinued SGLT-2i; 36 of them (40 %) due to onset of urogenital symptoms. We observed 6 cases of phimosis. Subjects who discontinued the treatment due to these side effects had a higher BMI and a better eGFR at baseline and they were less frequently treated with DPP-IV inhibitors.</div></div><div><h3>Conclusions</h3><div>A proper evaluation of the patient's phenotype might be useful in identifying subjects less prone to develop side effects driving SGLT-2i discontinuation; the combined use of SGLT-2i and DPP-IV inhibitors appears to be associated to a better long-term compliance to therapy in men.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109015"},"PeriodicalIF":2.9,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The burden of depression among patients with type 2 diabetes: An umbrella review of systematic reviews

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-19 DOI: 10.1016/j.jdiacomp.2025.109004

Nora Wulandari , Aly Lamuri , Fenneke van Hasselt , Talitha Feenstra , Katja Taxis

{"title":"The burden of depression among patients with type 2 diabetes: An umbrella review of systematic reviews","authors":"Nora Wulandari , Aly Lamuri , Fenneke van Hasselt , Talitha Feenstra , Katja Taxis","doi":"10.1016/j.jdiacomp.2025.109004","DOIUrl":"10.1016/j.jdiacomp.2025.109004","url":null,"abstract":"<div><h3>Objective</h3><div>Depression is common among patients with type 2 diabetes (T2D) which is a major global health concern. This umbrella review aims to explore differences in reported depression prevalence among people with type 2 diabetes and to identify the factors contributing to the variation.</div></div><div><h3>Methods</h3><div>A literature search was conducted in PubMed, EMBASE, PsycINFO and Cochrane. We included systematic reviews with or without a meta-analysis that investigated the prevalence of depression in adult patients (age 18 years or older) with T2D. Two independent reviewers screened titles and abstracts. The following data were extracted: study characteristics, depression assessment approach, and depression prevalence from systematic reviews and each primary study.</div></div><div><h3>Findings</h3><div>Of the 23 systematic reviews meeting inclusion criteria, comprising 649 unique primary studies, pooled depression prevalence ranged from 8.9 % to 61.6 %, with substantial heterogeneity (<em>I</em><sup>2</sup> values ranged from 89.41 % to 99.96 %). Studies conducted in the African (0.11 [95%CI 0.04–0.17]), Eastern Mediterranean (0.19 [95%CI 0.15–0.24]) and South-East Asia (0.08 [95%CI 0.03–0.13]) reported higher prevalence compared to the Americas. Additionally, studies utilizing screenings other than the Hamilton Depression Rating Scale (HDRS) exhibited lower prevalence rates (between −22 % and −0.10 %).</div></div><div><h3>Conclusion</h3><div>The burden of depression was high among people with T2D. Substantial variation was found in the prevalence of depression among individuals with T2D, depending on the WHO region and the depression assessment approach.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109004"},"PeriodicalIF":2.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143686053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-10 DOI: 10.1016/j.jdiacomp.2025.109000

Jocelynn King , Elizabeth Buschur , Rachel Garcetti , Laura Pyle , Casey Sakamoto , Janet Snell-Bergeon , Emily Nease , Anna Bartholomew , Kathleen Dungan , Sarit Polsky

{"title":"Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy","authors":"Jocelynn King , Elizabeth Buschur , Rachel Garcetti , Laura Pyle , Casey Sakamoto , Janet Snell-Bergeon , Emily Nease , Anna Bartholomew , Kathleen Dungan , Sarit Polsky","doi":"10.1016/j.jdiacomp.2025.109000","DOIUrl":"10.1016/j.jdiacomp.2025.109000","url":null,"abstract":"<div><h3>Aims</h3><div>We compared changes in insulin pump settings and insulin distribution throughout pregnancy and early postpartum for participants with type 1 diabetes using sensor-augmented pump therapy (SAPT) or hybrid closed-loop (HCL) therapy without a pregnancy-specific glucose target.</div></div><div><h3>Methods</h3><div>In this investigator-initiated trial 23 participants were randomized at 14–18 weeks gestation to HCL therapy or SAPT until 4–6 weeks postpartum. We compared the changes to insulin pump settings and insulin delivery between groups using mixed-effects models.</div></div><div><h3>Results</h3><div>There were no significant differences in total daily insulin dose between HCL and SAPT groups from preconception through 4–6 weeks postpartum. However, the proportion of total insulin coming from bolus insulin was higher for the HCL group in month 9 (70.9 % HCL vs 57.9 % SAPT, p = 0.014). The HCL group had a lower total daily basal dose compared to SAPT in months 9 and 10 (p < 0.05 for both) and a higher total daily bolus dose at month 10 compared to the SAPT group (55.2 units/day vs 37.1 units/day, p = 0.025). The number of changes to pump settings did not differ between groups. Active insulin time was significantly shorter in the HCL group at almost all time points through month 9 of pregnancy and early postpartum. Carbohydrate-to-insulin ratios were stronger for breakfast (p = 0.020) and lunch (p = 0.005) over gestation in the HCL group.</div></div><div><h3>Conclusion</h3><div>More bolus insulin and less basal insulin were used by the HCL group compared to the SAPT group, at least in part due to pump settings that contribute to more bolus insulin delivery.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109000"},"PeriodicalIF":2.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative analysis of the therapeutic effects of pregabalin, gabapentin, and duloxetine in diabetic peripheral neuropathy: A retrospective study

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-08 DOI: 10.1016/j.jdiacomp.2025.109001

Jiyong Ahn , Reza Shahriarirad , Kyeongeon Kwon , Lorena Bejarano-Pineda , Gregory Waryasz , Soheil Ashkani-Esfahani

{"title":"Comparative analysis of the therapeutic effects of pregabalin, gabapentin, and duloxetine in diabetic peripheral neuropathy: A retrospective study","authors":"Jiyong Ahn , Reza Shahriarirad , Kyeongeon Kwon , Lorena Bejarano-Pineda , Gregory Waryasz , Soheil Ashkani-Esfahani","doi":"10.1016/j.jdiacomp.2025.109001","DOIUrl":"10.1016/j.jdiacomp.2025.109001","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to compare the effects of pregabalin, gabapentin, and duloxetine on diabetic peripheral neuropathy (DPN) to guide tailored treatment.</div></div><div><h3>Materials and methods</h3><div>In this retrospective study, 180 patients with type 2 diabetes and DPN were matched 1:1:1 across three groups based on HbA1c and age, resulting in 60 patients per group. Clinical data were collected, and the painDETECT score was used to evaluate treatment response over six weeks.</div></div><div><h3>Results</h3><div>After six weeks, the gabapentin group had significantly higher pain scores than the pregabalin (P = 0.002) and duloxetine groups (P < 0.001). The pregabalin group's scores were higher than the duloxetine group's, but not significantly (P = 0.62). Side effects were more frequent with duloxetine (23.3 %) compared to gabapentin (1.7 %) and pregabalin (6.7 %) (P = 0.001). Among those with over 50 % improvement, mean HbA1c levels were 9.42 for gabapentin, 10.43 for pregabalin, and 7.72 for duloxetine. Duloxetine significantly lowered HbA1c compared to gabapentin (P = 0.001) and pregabalin (P = 0.001), with no significant difference between gabapentin and pregabalin (P = 0.45).</div></div><div><h3>Conclusion</h3><div>Duloxetine and pregabalin effectively treat DPN. Gabapentin and pregabalin are suitable for patients with HbA1c over 8.7, while duloxetine is better for those with well-controlled HbA1c. Treatment should consider side effects, adherence, costs, and response time.</div></div><div><h3>Level of the evidence</h3><div>Level III retrospective cohort study.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 109001"},"PeriodicalIF":2.9,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143619500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of non-surgical treatment in diabetes-associated periodontitis on immune/inflammatory and oxidative stress biomarkers: A pilot study

IF 2.9 3区医学

Journal of diabetes and its complications Pub Date : 2025-03-07 DOI: 10.1016/j.jdiacomp.2025.108999

Steffany Bernardo Oliveira , Ana Luíza Pereira Assunção Silveira , Yeon Jung Kim , Jônatas Bussador do Amaral , André Luis Lacerda Bachi , Margareth Afonso Torres , Karen Melissa Gonçalves Oliveira , Daniela Alves de Abreu , Leonardo Diniz Resende , Débora Pallos , Carolina Nunes França

{"title":"Effect of non-surgical treatment in diabetes-associated periodontitis on immune/inflammatory and oxidative stress biomarkers: A pilot study","authors":"Steffany Bernardo Oliveira , Ana Luíza Pereira Assunção Silveira , Yeon Jung Kim , Jônatas Bussador do Amaral , André Luis Lacerda Bachi , Margareth Afonso Torres , Karen Melissa Gonçalves Oliveira , Daniela Alves de Abreu , Leonardo Diniz Resende , Débora Pallos , Carolina Nunes França","doi":"10.1016/j.jdiacomp.2025.108999","DOIUrl":"10.1016/j.jdiacomp.2025.108999","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate the effects of non-surgical periodontal treatment on the levels of cytokines, sIgA, antimicrobial peptides, oxidative and antioxidative agents in comparison between patients with and without diabetes.</div></div><div><h3>Methods</h3><div>A case-control study that included patients (n = 45) with periodontitis who have or do not have diabetes. Cytokine concentrations in crevicular gingival fluid (GCF) and saliva were determined using LUMINEX and ELISA assays, respectively. Salivary levels of lysozyme, cathelicidin (LL-37), total antioxidant capacity (TAC) and total peroxide were determined colorimetrically before (T0) and one month after completion of periodontitis treatment (T1).</div></div><div><h3>Results</h3><div>There were no significant differences in the concentrations of cytokines in GCF between the groups and T0 and T1. Salivary concentrations of lysozyme and IL-10 were significantly reduced in T1 compared to T0 in the diabetes group (p = 0.0260 and p = 0.0034, respectively), whilst TNF-α concentration was higher in T1 (p = 0.0443). The salivary concentrations of TNF-α observed in the non-diabetes group at T1 decreased at T0 (p = 0.0313). The salivary concentration of TNF-α was increased in the diabetes group compared to the non-diabetes group at T1 (p = 0.0008).</div></div><div><h3>Conclusions</h3><div>An improvement in salivary inflammatory status was observed in the group without diabetes, which was not found in the group with diabetes after non-surgical periodontal treatment.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 4","pages":"Article 108999"},"PeriodicalIF":2.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143578984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0